Agendia to Present New FLEX Study Data at ASBrS 2026 Confirming the Consistent Performance of MammaPrint + BluePrint Across Diverse Racial Groups in Genomically Basal-Type Breast Cancer

May 1, 2026 Los Angeles Biotechnology Network News Los Angeles Biotech News Comments Off on Agendia to Present New FLEX Study Data at ASBrS 2026 Confirming the Consistent Performance of MammaPrint + BluePrint Across Diverse Racial Groups in Genomically Basal-Type Breast Cancer

IRVINE, Calif. & AMSTERDAM–(BUSINESS WIRE)–Multivariate analyses reveal that pCR is associated with transcriptomic differences and chemotherapy type, rather than self-reported race
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks